Skip Nav Destination
MRD in AML: time for redefinition of CR?
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease
Issue Archive
March 21 2013
In this Issue
Table of Contents
Inside Blood
CLINICAL TRIALS & OBSERVATIONS
MRD in AML: time for redefinition of CR?
Clinical Trials & Observations
Blood Work
Plenary Paper
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma
Maria Carmela Vegliante,Jara Palomero,Patricia Pérez-Galán,Gaël Roué,Giancarlo Castellano,Alba Navarro,Guillem Clot,Alexandra Moros,Helena Suárez-Cisneros,Sílvia Beà,Luis Hernández,Anna Enjuanes,Pedro Jares,Neus Villamor,Dolors Colomer,José Ignacio Martín-Subero,Elias Campo,Virginia Amador
Plenary Paper
Clonal architecture of chronic myelomonocytic leukemias
Raphaël Itzykson,Olivier Kosmider,Aline Renneville,Margot Morabito,Claude Preudhomme,Céline Berthon,Lionel Adès,Pierre Fenaux,Uwe Platzbecker,Olivier Gagey,Philippe Rameau,Guillaume Meurice,Cédric Oréar,François Delhommeau,Olivier A. Bernard,Michaela Fontenay,William Vainchenker,Nathalie Droin,Eric Solary
Review Article
Clinical Trials and Observations
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Clinical Trials & Observations
Eric Jourdan,for the French AML Intergroup,Nicolas Boissel,for the French AML Intergroup,Sylvie Chevret,for the French AML Intergroup,Eric Delabesse,for the French AML Intergroup,Aline Renneville,for the French AML Intergroup,Pascale Cornillet,for the French AML Intergroup,Odile Blanchet,for the French AML Intergroup,Jean-Michel Cayuela,for the French AML Intergroup,Christian Recher,for the French AML Intergroup,Emmanuel Raffoux,for the French AML Intergroup,Jacques Delaunay,for the French AML Intergroup,Arnaud Pigneux,for the French AML Intergroup,Claude-Eric Bulabois,for the French AML Intergroup,Céline Berthon,for the French AML Intergroup,Cécile Pautas,for the French AML Intergroup,Norbert Vey,for the French AML Intergroup,Bruno Lioure,for the French AML Intergroup,Xavier Thomas,for the French AML Intergroup,Isabelle Luquet,for the French AML Intergroup,Christine Terré,for the French AML Intergroup,Philippe Guardiola,for the French AML Intergroup,Marie C. Béné,for the French AML Intergroup,Claude Preudhomme,for the French AML Intergroup,Norbert Ifrah,for the French AML Intergroup,Hervé Dombret,for the French AML Intergroup
Gene Therapy
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells
Ashley T. Martino,Etiena Basner-Tschakarjan,David M. Markusic,Jonathan D. Finn,Christian Hinderer,Shangzhen Zhou,David A. Ostrov,Arun Srivastava,Hildegund C. J. Ertl,Cox Terhorst,Katherine A. High,Federico Mingozzi,Roland W. Herzog
Immunobiology
Lymphoid Neoplasia
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Marita Ziepert,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Claudia Becher,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Thomas F. E. Barth,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Heinz-Wolfram Bernd,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Alfred C. Feller,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Wolfram Klapper,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Michael Hummel,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Harald Stein,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Martin-Leo Hansmann,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Christopher Schmelter,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Peter Möller,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Sergio Cogliatti,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Michael Pfreundschuh,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Norbert Schmitz,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Lorenz Trümper,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Reiner Siebert,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Markus Loeffler,for the German High-Grade Non-Hodgkin Lymphoma Study Group,Andreas Rosenwald,for the German High-Grade Non-Hodgkin Lymphoma Study Group,German Ott,for the German High-Grade Non-Hodgkin Lymphoma Study Group
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
Sunil Iyengar,Andrew Clear,Csaba Bödör,Lenushka Maharaj,Abigail Lee,Maria Calaminici,Janet Matthews,Sameena Iqbal,Rebecca Auer,John Gribben,Simon Joel
Myeloid Neoplasia
Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia
Eva Diffner,Dominik Beck,Emma Gudgin,Julie A. I. Thoms,Kathy Knezevic,Clare Pridans,Sam Foster,Debbie Goode,Weng Khong Lim,Lies Boelen,Klaus H. Metzeler,Gos Micklem,Stefan K. Bohlander,Christian Buske,Alan Burnett,Katrin Ottersbach,George S. Vassiliou,Jake Olivier,Jason W. H. Wong,Berthold Göttgens,Brian J. Huntly,John E. Pimanda
Phagocytes, Granulocytes, and Myelopoiesis
Red Cells, Iron, and Erythropoiesis
The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys
Brief Report
Frank Schwoebel,Lucas T. van Eijk,Dirk Zboralski,Simone Sell,Klaus Buchner,Christian Maasch,Werner G. Purschke,Martin Humphrey,Stefan Zöllner,Dirk Eulberg,Frank Morich,Peter Pickkers,Sven Klussmann
Thrombosis and Hemostasis
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease
Brief Report
Jeroen Eikenboom,Augusto B. Federici,Richard J. Dirven,Giancarlo Castaman,Francesco Rodeghiero,Ulrich Budde,Reinhard Schneppenheim,Javier Batlle,Maria Teresa Canciani,Jenny Goudemand,Ian Peake,Anne Goodeve,the MCMDM-1VWD Study Group
Transplantation
Vascular Biology
Correspondence
Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome
Amy D. Klion,Rojelio Mejia,Edward W. Cowen,Kennichi C. Dowdell,Kieron Dunleavy,Gary A. Fahle,Nicole Holland-Thomas,Irina Maric,Stefania Pittaluga,Mark Raffeld,Carlo Santos,Maryalice Stetler-Stevenson,Tammy Krogmann,Amber N. Shatzer,Siu-Ping Turk,Yuzhi Yin,Liqiang Xi,Calman Prussin,Jeffrey I. Cohen
Errata
Continuing Medical Education (CME) Questions
-
Cover Image
Cover Image
Three-dimensional rendering of the mouse brain vasculature after mosaic gene targeting. Cells expressing the pro-angiogenic protein NRP1 appear purple and are found preferentially in tip cell positions, whilst cells lacking NRP1 appear turquoise and adopt stalk cell positions. Mosaic targeting of the Nrp1 gene was due to incomplete CRE-mediated recombination; NRP1 was labeled red, a YFP recombination reporter green, and the endothelial marker IB4 blue. See the article by Fantin et al on page 2352.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals